Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) corrected its announcement date and will provide a business update and report third quarter 2025 financial results on November 6, 2025, before Nasdaq market open. Executive Management will host a live conference call and webcast the same day at 14:30 CET / 08:30 EST to present results and take questions.
The event is free and open to the public; attendees should register in advance to receive dial-in numbers and a unique PIN for verbal questions. The call is accessible 15 minutes early and a webcast recording will be posted on the company website shortly after the event. Contact: Mads Kronborg, Vice President Investor Relations & Communication, +45 53 54 82 96, mak@evaxion.ai
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EVAX declined 0.17%, reflecting a mild negative market reaction. This price movement removed approximately $66K from the company's valuation, bringing the market cap to $39M at that time.
Data tracked by StockTitan Argus on the day of publication.
Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline.
COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Thursday November 6, 2025, before opening of the Nasdaq CM.
Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.
To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.
To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
About EVAXION
Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
When will Evaxion (EVAX) report third quarter 2025 results?
What time is the Evaxion (EVAX) conference call and webcast on November 6, 2025?
How do investors join the Evaxion (EVAX) November 6, 2025 call to ask questions?
Will Evaxion (EVAX) make a recording of the November 6, 2025 webcast available?
Can I access the Evaxion (EVAX) call before the scheduled start time on November 6, 2025?
Who is the investor relations contact for Evaxion (EVAX) regarding the November 6, 2025 results?
